Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023

Rhea-AI Summary

AUSTIN, Texas, March 09, 2023 – Lumos Pharma (NASDAQ:LUMO) announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, taking place virtually from March 13-15, 2023. Lumos Pharma will present on March 14 from 2:00-2:30 PM EDT and will host one-on-one meetings with investors on the same day. The presentation will focus on the company's oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) currently undergoing Phase 2 trials. Lumos Pharma’s lead candidate, LUM-201, has received Orphan Drug Designation in both the US and EU, offering a potential alternative to traditional growth hormone injections.

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33^rd Annual Healthcare Conference held virtually March 13-15, 2023. Lumos Pharma will present and host virtual one-on-one meetings with the investment community on Tuesday, March 14^th, during the event.

Event:                     Oppenheimer’s 33^rd Annual Healthcare Conference – March 13^th-15^th
Presentation:        Lumos Pharma Presentation March 14^th from 2:00-2:30PM EDT
Webcast link:        Here
1x1 Meetings:         Management will host one-on-one meetings with investors on Tuesday, March 14^th

The webcast for the presentation can also be found on the Company’s website under Events & Presentations in the Investors & Media section. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule 1x1 meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

When is Lumos Pharma presenting at the Oppenheimer Healthcare Conference 2023?

Lumos Pharma will present on March 14, 2023, from 2:00-2:30 PM EDT.

What is the focus of Lumos Pharma's presentation at the conference?

The presentation will focus on their oral therapeutic candidate for Pediatric Growth Hormone Deficiency.

What are the key dates for the Oppenheimer Healthcare Conference 2023?

The conference will take place from March 13-15, 2023.

What is LUM-201 and its significance?

LUM-201 is Lumos Pharma's lead candidate for treating Pediatric Growth Hormone Deficiency, offering an oral alternative to injections.

Has LUM-201 received any designations?

Yes, LUM-201 has received Orphan Drug Designation in both the US and EU.